Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis

2020 ◽  
Author(s):  
Smith Giri ◽  
Peter Barth ◽  
Luciano J. Costa ◽  
Adam J. Olszewski
Keyword(s):  
Older Adults ◽  
Multiple Myeloma ◽  
Population Based ◽  
Second Primary ◽  
First Line ◽  
Second Primary Malignancy ◽  
Primary Malignancy

The risk and prognosis of secondary primary malignancy in lung cancer: a population-based study

2021 ◽  
Author(s):  
Jia Hong ◽  
Rongrong Wei ◽  
Chuang Nie ◽  
Anastasiia Leonteva ◽  
Xu Han ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Cox Regression ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Risk Models ◽  
Primary Malignancy ◽  
Population Based Study ◽  
Competing Risk Models

Aim: To assess and predict risk and prognosis of lung cancer (LC) patients with second primary malignancy (SPM). Methods: LC patients diagnosed from 1992 to 2016 were obtained through the Surveillance, Epidemiology, and End Results database. Standardized incidence ratios were calculated to evaluate SPM risk. Cox regression and competing risk models were applied to assess the factors associated with overall survival, SPM development and LC-specific survival. Nomograms were built to predict SPM probability and overall survival. Results & conclusion: LC patients remain at higher risk of SPM even though the incidence declines. Patients with SPM have a better prognosis than patients without SPM. The consistency indexes for nomograms of SPM probability and overall survival are 0.605 (95% CI: 0.598–0.611) and 0.644 (95% CI: 0.638–0.650), respectively.

Observations of Second Primary Malignancy in Patients With Multiple Myeloma

2012 ◽  
Vol 12 (2) ◽  
pp. 113-117 ◽  
Author(s):  
Anne Ormerod ◽  
Christopher A. Fausel ◽  
Rafat Abonour ◽  
Patrick J. Kiel
Keyword(s):  
Multiple Myeloma ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy

scholarly journals Mortality of lung cancer as a second primary malignancy: A population‐based cohort study

2019 ◽  
Vol 8 (6) ◽  
pp. 3269-3277
Author(s):  
Lei Deng ◽  
Hrönn Harðardottír ◽  
Huan Song ◽  
Zhengrui Xiao ◽  
Changchuan Jiang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Population Based ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy

scholarly journals Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Abdullah M. Khan ◽  
Jameel Muzaffar ◽  
Hermant Murthy ◽  
John R. Wingard ◽  
Jan S. Moreb
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Acute Lymphoblastic Leukemia ◽  
Bone Marrow Biopsy ◽  
Lymphoblastic Leukemia ◽  
Second Primary ◽  
Cell Transplant ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Prognostic Features

Lenalidomide maintenance following autologous stem cell transplant (ASCT) is considered the standard of care for eligible patients with multiple myeloma (MM). A recent meta-analysis has provided additional evidence that lenalidomide maintenance is associated with a higher incidence of second primary malignancies, including both hematologic and solid malignancies. Acute lymphoblastic leukemia (ALL) as a second primary malignancy is rarely described in the literature. Herein, we describe two patients with MM treated with induction therapy, ASCT, and lenalidomide maintenance that experienced cytopenias while on maintenance. ALL was unexpectedly diagnosed on bone marrow biopsy. One patient was diagnosed on routine biopsy performed as part of requirements of the clinical trial. Both patients had B-cell ALL, without known poor risk cytogenetics, and were managed with standard induction therapies resulting in complete remission. We also reviewed the literature for similar cases of secondary ALL (sALL) in MM patients exposed to immunomodulatory drugs (IMiDs). In conclusion, persistent cytopenias in responding MM patients receiving IMiDs maintenance should be an indication for bone marrow biopsy. Patients develop sALL after median of 32.5 months (range, 20–84) from being on lenalidomide or thalidomide maintenance, often presenting with cytopenias, display low tolerance to chemotherapy, but remission can often be achieved.

scholarly journals Second primary malignancy after multiple myeloma-population trends and cause-specific mortality

2018 ◽  
Vol 182 (4) ◽  
pp. 513-520 ◽  
Author(s):  
Luciano J. Costa ◽  
Kelly N. Godby ◽  
Saurabh Chhabra ◽  
Robert Frank Cornell ◽  
Parameswaran Hari ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Population Trends ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Specific Mortality

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

Blood ◽  
2012 ◽  
Vol 119 (12) ◽  
pp. 2764-2767 ◽  
Author(s):  
Meletios A. Dimopoulos ◽  
Paul G. Richardson ◽  
Nancy Brandenburg ◽  
Zhinuan Yu ◽  
Donna M. Weber ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Pooled Analysis ◽  
Second Primary ◽  
Separate Analysis ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Pivotal Phase ◽  
Refractory Multiple Myeloma ◽  
Skin Cancers ◽  
Second Primary Malignancies

Abstract In a retrospective pooled analysis of 11 clinical trials of lenalidomide-based therapy for relapsed/refractory multiple myeloma (MM; N = 3846), the overall incidence rate (IR, events per 100 patient-years) of second primary malignancies (SPMs) was 3.62. IR of invasive (hematologic and solid tumor) SPMs was 2.08, consistent with the background incidence of developing cancer. In a separate analysis of pooled data from pivotal phase 3 trials of relapsed or refractory MM (N = 703), the overall IR of SPMs was 3.98 (95% confidence interval [CI], 2.51-6.31) with lenalidomide/dexamethasone and 1.38 (95% CI, 0.44-4.27) with placebo/dexamethasone; IRs of nonmelanoma skin cancers were 2.40 (95% CI, 1.33-4.33) and 0.91 (95% CI, 0.23-3.66), respectively; IRs of invasive SPMs were 1.71 (95% CI, 0.86-3.43) and 0.91 (95% CI, 0.23-3.66), respectively. The risk of SPMs must be taken into account before initiating lenalidomide treatment. In the context of the observed survival benefit in relapsed or refractory MM patients, the benefit/risk profile of lenalidomide/dexamethasone remains positive.

scholarly journals The risk of second primary malignancy in patients with stage Ia non-small cell lung cancer: a U.S. population-based study

2017 ◽  
Vol 57 (2) ◽  
pp. 239-243 ◽  
Author(s):  
Amit Khanal ◽  
Bilal Haider Lashari ◽  
Sreechandralekha Kruthiventi ◽  
Lubina Arjyal ◽  
Amir Bista ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Population Based ◽  
Small Cell ◽  
Second Primary ◽  
Small Cell Lung ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Population Based Study ◽  
Stage Ia
Sign in / Sign up

Export Citation Format

Share Document